Skip to main content

Table 2 Clinical data profile of pre- and post-pitavastatin treatment

From: Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association

Variables n baseline n Post-treatment Change (%) P value
Body weight (kg) 53 64.1 ± 15.4 52 64.4 ± 16.2 0.7 ± 2.4 0.052
HbAlc (%) 53 7.1 ± 0.80 53 7.2 ± 0.84 1.6 ± 7.6 0.13
eGFR (ml/min/m2) 52 75.4 ± 16.9 51 76.8 ± 16.5 4.2 ± 17.2 0.18
BUN (mg/dL) 52 14.7 ± 4.2 50 14.8 ± 3.9 −2.3 ± 23.8 0.49
Uric acid (mg/dL) 52 5.2 ± 1.4 51 4.9 ± 1.2 −4.7 ± 14.1 0.02
TC (mg/dL) 53 234.3 ± 28.9 48 173.0 ± 25.8 −25.7 ± 9.9 <0.01
TG (mg/dL) 53 146.7 ± 74.1 48 134.2 ± 87.0 −4.1 ± 55.3 0.61
HDL-C (mg/dL) 53 58.8 ± 14.8 49 58.7 ± 15.5 −0.6 ± 11.4 0.7
LDL-C (mg/dL) 53 152.1 ± 29.2 49 91.2 ± 25.4 −39.4 ± 13.6 <0.01
sd LDL-C (mg/dL) 53 52.0 ± 18.1 49 28.7 ± 10.4 −41.7 ± 18.0 <0.01
sd LDL-C/LDL-C (%) 53 33.9 ± 8.4 49 31.6 ± 7.3 −4.5 ± 15.6 0.047
ApoA-I (mg/dL) 53 142.9 ± 26.6 48 148.5 ± 26.7 3.5 ± 8.4 <0.01
CETP (μg/mL) 48 2.54 ± 0.60 46 1.98 ± 0.73 −22.9 ± 19.5 < 0.01